School of Pharmaceutical Sciences, Universiti Sains Malaysia

  • Qualification

    PhD (Medicinal chemistry)(NUS), BPharm(Hons)(USM), RPh.

  • Senior Lecturer

    Discipline of Pharmaceutical Chemistry

  • Room

    J02 Room 135

  • Contact

    +604-6577888 Ext. 4086

  • Email

    chongyew@usm.my

Author ID
  • Looking for PhD students

    Discovering new spiroindolone-type compounds as microglia modulators for Alzheimer's disease - 3 years

  • Looking for Final Year Project Student

    Isolation of bioactive alkaloids from Fritillaria bulbs (川贝母) - 2 years

Lee Chong Yew, Dr

Dr. Lee is a passionate and dedicated educator in the field of pharmaceutical and medicinal chemistry. He is committed to instilling in his students an understanding of the vital role that chemistry plays in pharmacy. Dr. Lee's research focuses on lead optimization for the discovery of new drug-like compounds that have the potential to become future medications, as well as pharmacokinetics, systematic reviews and meta-analysis, pharmacy practice, and the use of nanomaterials as innovative therapeutic and drug delivery platforms. He has also authored and published a multitude of articles in various academic journals.

  • Research Interest

    1. Lead optimization to discover drug-like compounds with therapeutic potentials
    2. Pharmacokinetics of drug-like compound
    3. Systematic reviews and meta-analysis on the efficacy and safety of medicines
    4. Nanomaterials as therapeutic platforms and wearables
    5. Pharmacy practice

    Ongoing Research

    1. Discovering new spiroindolone-type compounds as microglia modulators for Alzheimer's disease
    1. Medicinal chemistry
    2. Organic synthesis
    3. Lead optimization
    4. NMR spectroscopy
    5. Meta-analysis
    6. Nanomaterials
    7. Future medicines
    1. Lim P.C., Yap B.K., Tay Y.J., Hanapi N.A., Yusof S.R., Lee C.Y. (2024). Discovery of aurones bearing two amine functionalities as SHIP2 inhibitors with insulin-sensitizing effect in rat myotubes. RSC Med. Chem. Article in Press. doi: 10.1039/D3MD00360D.
    2. Chia S.Y., Khor B.K., Tay Y.J., Liew K.F., Lee C.Y. (2023). Discovery of blood-brain barrier permeant amine-functionalized aurones as inhibitors of activated microglia. Bioorg. Chem. 135:106509. doi: 10.1016/j.bioorg.2023.106509
    3. Hipolith M.M., Khor B.K., Hirasawa Y., Murugaiyah V., Lee C.Y., Morita H., Wong P.F., Chan K.L. (2023). Quassinoids from Eurycoma longifolia Jack roots and their potential inhibitory activity against human benign prostatic hyperplasia cells (BPH-1) and testosterone-induced BPH rat model. Fitoterapia. 166:105468. doi: 10.1016/j.fitote.2023.105468
    4. Yew K.C., Tan Q.R., Lim P.C., Low W.Y., Lee C.Y. (2023). Assessing the impact of direct-acting antivirals on hepatitis C complications: a systematic review and meta-analysis. Naunyn Schmiedebergs Arch Pharmacol. Article in Press. doi: 10.1007/s00210-023-02716-x
    5. Lim P.C., Rajah R., Wong K.L., Chong M.F., Chow T.S., Subramaniam S., Lee C.Y. (2022). Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis. DARU J. Pharm. Sci. 30: 211-228. doi: 10.1007/s40199-021-00430-8
    6. Yang Y., Wei X., Zhang N., Zheng J., Chen X., Wen Q., Luo X., Lee C.Y., Liu X., Zhang X., Chen J., Tao C., Zhang W., Fan X. (2021). A non-printed integrated-circuit textile for wireless theranostics. Nature Commun.12: 4876. doi: 10.1038/s41467-021-25075-8
    7. Ramachandran P., Lee C.Y., Doong R.A., Oon C.E., Kim Thanh N.T., Lee H.L. (2020). A titanium dioxide/nitrogen-doped graphene quantum dot nanocomposite to mitigate cytotoxicity: synthesis, characterisation, and cell viability evaluation. RSC Adv. 10(37):21795-21805. doi: 10.1039/d0ra02907f.
    8. Lee E.H.C., Lim S.C., Yuen K.H., Lee C.Y. (2019). Curcumin and a Hemi-analogue with Improved Blood-brain Barrier Permeability Protect Against Amyloid-beta Toxicity in Caenorhabditis elegans via SKN-1/Nrf Activation. J. Pharm. Pharmacol. 71: 860-868. doi: 10.1111/jphp.13052
    9. Liew K.F., Hanapi, N.A., Chan K.L., Yusof S.R., Lee C.Y. (2017). Assessment of the Blood-Brain Barrier of Potential Neuroprotective Aurones in Parallel Artificial Membrane Permeability Assay and Porcine Brain Endothelial Cell Models. J. Pharm. Sci. 106(2): 502 -510. doi: 10.1016/j.xphs.2016.10.006
    10. Liew K.F., Chan K.L., Lee C.Y. (2015). Blood-brain Barrier Permeable Anticholinesterase Aurones: Synthesis, Structure-activity Relationship, and Drug-like Properties. Eur. J. Med. Chem. 94: 195-210. doi: 10.1016/j.ejmech.2015.02.055
    1. FAR115 Principles of Medicinal Chemistry
    2. FAR240 Peripheral Nervous System and Therapy
    3. FAR244 Endocrine System and Reproductive System and Therapy
    4. FAR 344 Central Nervous System and Therapy
    1. NMR spectroscopy and structure elucidation

  • Journal Reviewer

    1. Journal of Medicinal Chemistry
    2. ACS Chemical Neuroscience
    3. ACS Molecular Pharmaceutics
    4. Bioorganic Chemistry
    5. Journal of Pharmacy & Pharmacology
    6. Archive Der Pharmazie
    7. Medicinal Chemistry Communications.
    1. Peter R. Guzzo, Alan J. Henderson, Matthew Isherwood, Chong Yew Lee, Animesh Ghosh, He Zhao (2015). Benzofuro[3, 2-c]pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia. US Patent 9,067,949.
    2. Chong Yew Lee, Siti Rafidah Yusof. Benzylidenebenzofuran-3(2H)-ones (aurones) as SH2-domain-containing inositol phosphatase 2 (SHIP2) inhibitors for the treatment of insulin resistance, diabetes mellitus and metabolic syndrome. PI2023 002116.
    1. Sanggar Sanjung for Publication (2015, 2021)
    2. Travel Grant for Emerging Therapeutics Summit 2016

School of Pharmaceutical Sciences
11800 Universiti Sains Malaysia, Pulau Pinang, Malaysia.
Tel : . 04-653 3812 | Fax: +604-657 0017

  • Last Modified:
    Isnin 11 November 2024, 12:52:24.